At a glance
- Originator Bristol-Myers Squibb
- Class Antirheumatics; Macrocyclic compounds
- Mechanism of Action Immunosuppressants; Matrix metalloproteinase inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 08 Jul 2008 Discontinued - Preclinical for Osteoarthritis in USA (PO)
- 08 Jul 2008 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)
- 15 Sep 1999 New profile